TNF and inflammatory bowel disease: Infliximab, a monoclonal antibody targeting tumor necrosis factor alpha (TNFα), is usually considered as the preferred second-line therapy, due to its ability to induce a rapid clinical response, analogous to its established efficacy in the treatment of inflammatory bowel disease (IBD) [12,13].